Cytokine gene polymorphisms, cancer susceptibility, and prognosis

Journal of Nutrition

Volumn 137, Issue 1, 2007, Pages

  Howell, W Martin ^a   Rose Zerilli, Matthew J ^b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; ESTROGEN RECEPTOR; FISH OIL; INTERLEUKIN 10; PROGESTERONE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

BREAST CANCER; CANCER RISK; CONFERENCE PAPER; DIET SUPPLEMENTATION; DISEASE COURSE; DISEASE PREDISPOSITION; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETIC TRANSCRIPTION; GENOTYPE; HAPLOTYPE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PROGNOSIS; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 33846017628     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.1093/jn/137.1.194s     Document Type: Conference Paper

References (62)

1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994;266:66-71.
2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, Collins N, Gregory S, Gumbs C, Micklem G. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378:789-92.
3. Blackwood MA, Weber BL. BRCA1 and BRCA2: from molecular genetics to clinical medicine. J Clin Oncol. 1998;16:1969-77.
4. Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, Brownstein MJ, Bova GS, Guo H, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 1996;274:1371-4.
5. Xu J, Meyers D, Freije D, Isaacs S, Wiley K, Nusskern D, Ewing C, Wilkens E, Bujnovszky P, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998;20:175-9.
6. Ford D, Easton DF, Bishop DT, Narod SA, Goldger DE. Risk of cancer in BRCA1 mutation carriers. Lancet. 1994;343:692-5.
7. Gibbs M, Stanford JL, McIndoe RA, Jarvik GP, Kolb S, Goode EL, Chakrabarti L, Schuster EF, Buckley VA, et al. Evidence for a rare prostate cancer-susceptibility locus at chromosome 1p36. Am J Hum Genet. 1999;64:776-87.
8. Berthon P, Valeri A, Cohen-Akenine A, Drelon E, Paiss T, Wohr G, Latil A, Millasseau P, Mellah I, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet. 1998;62:1416-24.
9. Tavtigian SV, Simard J, Teng DH, Abtin V, Baumgard M, Beck A, Camp NJ, Carillo AR, Chen Y, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. 2001;27:172-80.
10. Nathanson K, Weber BL. Other breast cancer susceptibility genes: searching for more holy grail. Hum Mol Genet. 2001;10:715-20.
11. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33-6.
12. Charrier J, Maugard CM, LeMevel B, Bignon YJ. Allelotype influence at glutathione S-transferase M1 locus on breast cancer susceptibility. Br J Cancer. 1999;79:346-53.
13. Bergman-Jungestrom M, Gentile M, Lundin A, Wingren S. Association between CYP17 gene polymorphism and risk of breast cancer in young women. Int J Cancer. 1999;84:350-3.
14. Dunning AM, Healey CS, Pharaoh PDP, Teare MD, Ponder BAJ, Easton DF. A systematic review of genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomark Prev. 1999;8:843-54.
15. Bateman AC, Howell WM. Human leukocyte antigens and cancer: is it in our genes? J Pathol. 1999;188:231-6.
16. Bidwell J, Keen L, Gallagher G, Kimberley R, Huizinga T, McDermott MF, Oksenberg J, McNicholl J, Pociot F, et al. Cytokine gene polymorphism in human disease: on-line databases. Genes Immun. 1999;1:3-19.
17. Haukim N, Bidwell JL, Smith AJP, Keen LJ, Gallagher G, Kimberley R, Huizinga T, McDermott MF, Oksenberg J, et al. Cytokine gene polymorphism in human disease: on-line databases, Supplement 2. Genes Immun. 2002;3:313-30.
18. Grimble RF, Howell WM, O'Reilly GR, Turner SJ, Markovic O, Hirrell S, East JM, Calder PC. The ability of fish oil to supress tumor necrosis factor a production by periperhal blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor 2 production. Am J Clin Nutr. 2002;76:454-9.
19. Demeter J, Porzsolt F, Ramisch S, Schmidt D, Schmid M, Messer G. Polymorphism of the tumour necrosis factor-alpha and lymphotoxin-alpha genes in chronic lymphocytic leukaemia. Br J Haematol. 1997;97:107-12.
20. Warzocha K, Ribeiro P, Bienvenu J, Roy P, Charlot C, Rigal D, Coiffier B, Salles G. Genetic polymorphisms in the tumour necrosis factor locus influence non-Hodgkin's lymphoma outcome. Blood. 1998;91:3574-81.
21. Mestiri S, Bouaouina N, Ahmed SB, Khedhaier A, Jrad AA, Remadi S, Chouchane L. Genetic variation in the tumour necrosis factor-α promoter region and in the stress protein hsp70-2. Cancer. 2001;91:672-8.
22. Wihlborg C, Sjoberg J, Intaglietta M, Axdorph U, Pisa EK, Pisa P. Tumour necrosis factor-α cytokine promoter polymorphism in Hodgkin's disease and chronic lymphocytic leukaemia. Br J Haematol. 1999;104:346-9.
23. Park KS, Mok JW, Ko HE, Tokunga K, Lee MH. Polymorphisms of tumour necrosis factors A and B in breast cancer. Eur J Immunogenet. 2002;29:7-10.
24. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JH, Young HA, Herrera J, Lissowska J, Yuan CC, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398-402.
25. Eskdale J, Kube D, Tesch H, Gallagher G. Mapping of the human IL-10 gene and further characterisation of the 5′ flanking sequence. Immunogenetics. 1997;46:120-8.
26. European Bioinformatics Institute, Sanger Institute. SNP database: Ensembl Genome Browser. 2006. Available at: http://www.ensembl.org/index.html.
27. Howell WM. Interleukin-10 gene polymorphisms and cancer. In Marincola FM, editor. Interleukin-10. Eurekah.com; 1-17.
28. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the Interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1-8.
29. Crawley E, Kay R, Sillibourne J, Patel P, Hutchinson I, Woo P. polymorphic haplotypes of the interleukin-10 5′ flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis. Arthritis Rheum. 1999;42:1101-8.
30. Hoffmann SC, Stanley EM, Darrin Cox E, Craighead N, DiMercurio BS, Koziol DE, Harlan DM, Kirk AD, Blair PJ. Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation. 2001;72:1444-50.
31. Reuss E, Fimmers R, Kruger A, Becker C, Rittner C, Hohler T. Differential regulation of Interleukin-10 production by genetic and environmental factors: a twin study Genes and Immun 2002;3:407-13.
32. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proc Natl Acad Sci USA. 1998;95:9465-70.
33. Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349:170-3.
34. Howell WM, Turner SJ, Bateman AC, Theaker JM. IL-10 promoter polymorphisms influence tumour development in cutaneous malignant melanoma. Genes Immun. 2001;2:25-31.
35. Martinez-Escribano JA, Moya-Quiles MR, Muro M, Montes-Ares O, Hernandez-Casselles T, Finas JF, Alvarez-Lopez MR. Interleukin-10, Interleukin-6 and interferon-γ gene polymorphisms in melanoma patients. Melanoma Res. 2002;12:465-9.
36. McCarron SL, Edwards S, Evans PR, Gibbs R, Dearnaley DP, Dowe A, Southgate C, Easton DF, Eeles RA, Howell WM. Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res. 2002;62:3369-72.
37. Michaud DS, Daugherty SE, Berndt SI, Platz EA, Yeager M, Crawford ED, Hsing A, Huang WY, Hayes RB. Genetic polymorphisms of interleukin-1B (IL-1B), IL-6, IL-8, and IL-10 and risk of prostate cancer. Cancer Res. 2006;66:4525-30.
38. Smith KC, Bateman AC, Fussell HM, Howell WM. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur J Immunogenet. 2004;31:167-73.
39. Giordani L, Bruzzi P, Lasalandra C, Quaranta M, Schittulli F, Della Ragione F, Iolascon A. Polymorphisms of Interleukin-10 and tumour necrosis factor-α gene promoter and breast cancer risk. Clin Chem. 2003;49:1664-7.
40. Langsenlehner U, Krippl P, Renner W, Yazdani-Biuki B, Eder T, Koppel H, Wascher TC, Paulweber B, Samonigg H. Interleukin-10 promoter polymorphism is associated with decreased breast cancer risk. Breast Cancer Res Treat. 2005;90:113-5.
41. Bulpitt EA, Baynes C, Dunning AM, Evans PR, Easton DF, Ponder BAJ, Gibbs R, Howell WM. Investigation of interleukin-10 and vascular endothelial growth factor single nucleotide polymorphisms in predisposition to breast cancer. Genes Immun. 2004;5: Suppl. 1:S53.
42. Stanczuk GA, Sibanda EN, Perrey C, Chicara M, Pravica V, Hutchinson IV, Tswana SA. Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. Int J Cancer. 2001;94:792-4.
43. Roh JW, Kim MH, Seo SS, Kim SH, Kim JW, Park NH, Song YS, Park SY, Kang SB, Lee HP. Interleukin-10 promoter polymorphisms and cervical cancer risk in Korean women. Cancer Lett. 2002;184:57-63.
44. Wu M-S, Wu C-Y, Chen C-J, Lin MT, Shun CT, Lin JT. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer. 2003;104:617-23.
45. Wu M-S, Huang S-P, Chang Y-T, Shun CT, Chang MC, Lin MT, Wang HP, Lin JT. Tumour necrosis factor-α and Interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis. 2002;185:106-9.
46. El-Omar EM, Rabkin CS, Gammon MD, Vaughan TL, Risch HA, Schoenberg JB, Stanford JL, Mayne ST, Goedert J, et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology. 2003;124:1193-201.
47. Alamartine E, Berthoux E, Mariat C, Cambazard F, Berthoux F. Interleukin-10 promoter polymorphisms and susceptibility to skin squamous cell carcinoma after renal transplantation. J Invest Dermatol. 2003;120:99-103.
48. Shin HD, Park BL, Kim LH, Jung JH, Kim JY, Yoon JH, Kim YJ, Lee HS. Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet. 2003;12:901-6.
49. Havranek E, Howell WM, Fussell HM, Whelan JA, Whelan MA, Pandha HS. An IL-10 promoter polymorphism may influence tumour development in renal cell carinoma. J Urol. 2005;173:709-12.
50. Zheng C, Huang D, Liu L, Wu R, Bergenbrant Glas S, Osterborg A, Bjorkholm M, Holm G, Yi Q, Sundblad A. Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer. 2001;95:184-8.
51. Gowans D, O'Sullivan A, Rollison S, Roddam P, Groves M, Fegan C, Morgan G, Bowen D. Allele and haplotype frequency at human leucocyte antigen class I/II and immunomodulatory cytokine loci in patients with myelodysplasia and acute myeloid leukaemia: in search of an autoimmune aetiology. Br J Haematol. 2002;117:541-5.
52. Cunningham LM, Chapman C, Dunstan R, Bell MC, Joske DJ. Polymorphisms in the interleukin 10 gene promoter are associated with susceptibility to aggressive non-Hodgkin's lymphoma. Leuk Lymphoma. 2003;44:251-5.
53. Breen EC, Boscardin WJ, Detels R, Jacobson LP, SmithMW, O'Brien SJ, Chmiel JS, Rinaldo CR, Lai S, Martinez-Maza O. Non-Hodgkin's B cell lymphoma in persons with acquired immunodeficiency syndrome is associated with increased serum levels of IL-10, or the IL-10 promoter 2592 C/C genotype. Clin Immunol. 2003;109:119-29.
54. Lech-Maranda E, Baseggio L, Bienvenu J, Charlot C, Berger F, Rigal D, Warzocha K, Coiffier B, Salles B. Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma. Blood. 2004;103:3529-34.
55. Munro LR, Johnston PW, Marshall NA, Canning SJ, Hewitt SG, Tveita K, Vickers MA. Polymorphisms in the interleukin-10 and interferon gamma genes in Hodgkin lymphoma. Leuk Lymphoma. 2003;44:2083-8.
56. Lauten M, Matthias T, Stanulla M, Berger C, Welte K, Schrappe M. Association of initial response to prednisone treatment in childhood acute leukaemia and polymorphism within the tumour necrosis factor and the Interleukin-10 gene. Leukemia. 2002;16:1437-42.
57. DeMichele A, Martin AM, Mick R, Gor P, Wray L, Klein-Cabral M, Athanasiadis G, Colligan T, Stadtmauer E, Weber B. Interleukin-6 -174 G/C polymorphism is associated with improved outcome in high risk breast cancer. Cancer Res. 2003;63:8051-6.
58. Ito LS, Iwata H, Hamajima N, Saito T, Matsuo K, Mizutani M, Iwase T, Miura S, Okuma K, et al. Significant reduction in breast cancer risk for Japanese women with interleukin1B -31CT/TT relative to CC genotype. Jpn J Clin Oncol. 2002;32:398-402.
59. Saha A, Gupta V, Bairwa NK, Malhotra D, Bamezai R. Transforming growth factor-bta1 genotype in sporadic breast cancer patients from India: status of enhancer, promoter, 5′-untranslated-region and exon-1 polymorphisms. Eur J Immunogenet. 2004;31:37-42.
60. Lee KM, Park SK, Hamajima N, Tajima K, Yoo KY, Shin A, Noh DY, Ahn SH, Hirvonen A, Kang D. Genetic polymorphisms of TGF-beta 1 and TNF-beta and breast cancer risk. Breast Cancer Res Treat. 2005;90:149-55.
61. Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, et al. A transforming growth factor beta 1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res. 2003;63:2610-5.
62. Barrett JH, Thomson W, Ollier W. HLA and disease association: statistical considerations. In Bidwell JL, Navarrete C, editors. Histocompatibility Testing. London: Imperial College Press; 2000, pp. 439-452.